Post Title

13 Dec: aptaTargets gets new funding from the RETOS-program for exploring inflammatory pathologies

A Consortium led by AptaTargets has been awarded with public funding from the RETOS program for exploring new indications for ApTOLL, a DNA aptamer targeting TLR4 with an anti-inflammatory effect. The Consortium RETOS-SafeTOLL (RTC-2017-6283-1) is also composed by the Neurovascular Research Unit (Complutense University, Madrid) and the Institute of Biomedical Research (UAM-CSIC, Madrid) and has a total budget of 503,800 EU.

13 Dec: RETOS funding for the ApTOLL stroke program

AptaTargets is the leader of the NeuroToll project, aiming to the clinical development of ApTOLL, an innovative neuroprotective drug for the acute treatment of stroke. The project focuses in stroke program, advancing from late preclinical phase and up to clinical trials Phase II in stroke patients. The project has obtained funding from the Ministry of Science, Innovation and Universities through the RETOS-COLABORACION program, which includes FEDER funding (RTC-2017-6651-1). The consortium is formed by AptaTargets along with several hospitals of reference in the stroke field, such as Germans Trias i Pujol (HGTiP, Barcelona), La Princesa (HULP, Madrid), Virgen del Rocio and Macarena (FISEVI, Sevilla). The project has an aggregated budget of around 3.1 M EU.

14 Mar: aptaTargets gets funds from NEOTEC Program

The Spanish Centre for the Development of Industrial Technology (CDTI) has granted AptaTargets with funds from the Neotec Program. AptaTargets aims to advance in the pre-clinical and clinical development of ApToll (a molecule based on aptamer technology and targeting inflammation) in acute ischemic stroke and other indications (myocardial infarction and Multiple Sclerosis).

14 Dec: ApTOLL gets funds from Retos-2015 Program

The ApTOLL project aims to advance in the preclinical development of a molecule based on aptamer technology for acute stroke and myocardial infarction. The consortium is led by the company AptaTargets and are also participating Aptus Biotech, the Neurovascular Research Unit (Complutense University) and the Institute of Biomedical Research (UAM-CSIC). The project is funded by the Ministry of Economy and Competitiveness and funds from the European Union, within the objective of promoting the technological development, innovation and research.